Why retatrutide buyers convert 2× better than semaglutide-only buyers

Most telehealth brands acquire GLP-1 prospects as if all GLP-1 buyers are interchangeable. Our data says they're not.

Across 1,945 transaction-verified GLP-1 purchases in our inventory, we segmented by which compound the buyer actually purchased: retatrutide, tirzepatide, semaglutide, or compound blends. The behavioral differences are sharp enough that "GLP-1 buyer" as a single audience is masking real economic heterogeneity.

The data

• Retatrutide buyers (n=1,123): average documented spend $342, repeat-purchase rate 38%, average price-per-purchase $124
• Tirzepatide buyers (n=540): average documented spend $267, repeat-purchase rate 31%, average price-per-purchase $98
• Semaglutide-only buyers (n=282): average documented spend $171, repeat-purchase rate 22%, average price-per-purchase $89

Retatrutide buyers spend 2× what semaglutide-only buyers spend and repeat-purchase at 1.7× the rate.

What's driving the difference

Three things, all interlocking:

1. Information asymmetry as filter. Retatrutide is a triple-agonist (GIP/GLP-1/glucagon) that hit FDA approval pathways more recently and isn't yet broadly available through standard insurance pathways. Buyers reaching it have done their research — they know what compound they want, why, and they're prepared to pay cash for it. That self-selection alone would predict higher AOV.

2. Newness premium. Within the GLP-1 category, retatrutide is the cutting edge. Buyers who orient toward newest-available compounds tend to be early adopters in adjacent categories too. They cross-buy more peptides, more hormones, more recovery stacks. The retatrutide signal correlates with multi-category behavior.

3. Underwriting bias. Retatrutide is priced higher per dose at most compounding sources. The buyer self-selecting at that price point is, on average, less price-sensitive across the rest of their spending. This shows up in our card-brand data: retatrutide buyers are 1.4× more likely to be Amex holders than semaglutide-only buyers.

The telehealth acquisition implication

If you run a telehealth GLP-1 brand, segmenting your paid acquisition by compound preference is one of the highest-leverage targeting moves available.

Spend more per lead on the retatrutide cohort. The unit economics math works at $80-100/lead exclusive vs $30-50/lead for semaglutide-only — because the LTV math compounds: retatrutide buyers are roughly 2× more likely to upgrade to your premium concierge tier, more likely to add complementary peptides, more likely to refer.

The opposite is also true: if you're a budget-positioned brand competing on price, semaglutide-only buyers may convert at acceptable rates at lower acquisition cost. Match price-point to acquisition-tier.

What we don't yet know

We don't have sufficient data on cagrilintide (the amylin analog increasingly blended with semaglutide) or on next-generation candidates like orforglipron (the recent oral GLP-1 small molecule) to publish reliable behavioral segments. We expect cagrilintide blends to behave more like retatrutide buyers (early adopter premium) than like semaglutide-only.

Bottom line

"GLP-1 buyer" is too coarse a segment to make economic decisions on. Compound preference is a sharper signal than category, and it predicts spend and retention more reliably than card brand or geography.

Pepleadz inventory tags dominant compound on every record. Buyers can filter explicitly for retatrutide-buyers (1,123 in inventory) or any combination of the GLP-1 compound family. Use that lens.

Acquire the right cohort. Don't pay for the wrong one.